Feature

Sickle cell patients suffer discrimination, poor care – and shorter lives


 

“I’m sure we tested over four-and-a-half-thousand people for sickle cell anemia last night – and I think that the voter registration is running neck and neck with it,” Black Panther Party Chairman Bobby Seale told news crews at an event in Oakland in 1972.

The movement grew, and Washington listened. “It is a sad and shameful fact that the causes of this disease have been largely neglected throughout our history,” President Richard Nixon told Congress in 1971. “We cannot rewrite this record of neglect, but we can reverse it. To this end, this administration is increasing its budget for research and treatment of sickle cell disease.”

For a while, funding did increase, newborn screening took hold, and by the 1990s, life expectancy had doubled, with patients living into their 40s. But over time, funding waned, clinics closed, and life expectancy started dropping again.

Dr. Vichinsky pushes against that trend for patients like Derek Perkins. The father of four looks healthy and robust, but like most sickle cell patients, he has episodes of extreme pain and has problems with his kidneys, heart, hips, and breathing. Keeping him thriving requires regular checkups and constant monitoring for potential problems.

“The program Dr. Vichinsky is running here, I feel I owe my life to [it],” said Mr. Perkins. “If it wasn’t for him and the things that he did for me, my family wouldn’t have me.”

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation. KHN’s coverage of children’s health care issues is supported in part by a grant from The Heising-Simons Foundation.

Pages

Recommended Reading

Study advances noninvasive prenatal testing for hemophilia
MDedge Hematology and Oncology
Disseminated Intravascular Coagulation
MDedge Hematology and Oncology
Product can improve joint health in hemophilia A
MDedge Hematology and Oncology
Hemophilia B therapy approved in Saudi Arabia
MDedge Hematology and Oncology
Gene therapy granted orphan designation for hemophilia A
MDedge Hematology and Oncology
Eltrombopag can control ITP long-term, study suggests
MDedge Hematology and Oncology
Caplacizumab may enhance treatment of aTTP
MDedge Hematology and Oncology
Japan approves product for hemophilia A
MDedge Hematology and Oncology
FDA grants factor IX therapy orphan designation
MDedge Hematology and Oncology
EMA issues final opinion on FVIII products
MDedge Hematology and Oncology